Company Overview of The Multiple Myeloma Research Foundation, Inc
Key Executives for The Multiple Myeloma Research Foundation, Inc
Chief Executive Officer, President and Chief Operating Officer
Founder and Executive Chairman
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2015.
The Multiple Myeloma Research Foundation, Inc Key Developments
Multiple Myeloma Research Foundation Partners with Janssen Biotech, Inc. on Daratumumab Expanded Access Program
Jul 7 15
The Multiple Myeloma Research Foundation announced its collaboration with Janssen Biotech, Inc. on the daratumumab expanded access program, which launched for eligible multiple myeloma patients in the United States. Daratumumab is an investigational human anti-CD38 monoclonal antibody currently being evaluated as a potential multiple myeloma monotherapy treatment. EAPs allow pharmaceutical companies to make investigational therapies available to patients with serious or life-threatening diseases that are not helped by currently available treatment options. The multicenter, open-label daratumumab EAP is available to multiple myeloma patients who are double refractory to both a proteasome inhibitor and an immunomodulatory drug or who have received three or more prior lines of therapy. The MMRF has worked with Janssen in identifying sites across the U.S. and supporting its efforts for enrolling patients. Approximately half of the 40 medical centers involved in the EAP are MMRF partner institutions that comprise the Multiple Myeloma Research Consortium (MMRC). Previously in 2011, the MMRF partnered with Onyx Pharmaceuticals, Inc. on an EAP for carfilzomib (Kyprolis). The daratumumab EAP has specific inclusion and exclusion criteria for patients to be considered for enrollment in the program. Patients should contact their physician if they believe they are eligible or if they want to learn more.
Multiple Myeloma Research Foundation, University of Torino and Adaptive Biotechnologies Work to Speed Novel Minimal Residual Disease Monitoring Technologies to Patients
Apr 14 15
The Multiple Myeloma Research Foundation (MMRF), in collaboration with the University of Torino (UofT) and Adaptive Biotechnologies, announced a collaboration to perform sequencing-based assessment of minimal residual disease (MRD) on hundreds of multiple myeloma (MM) patients over a five year period. The purpose of this initiative is to investigate a new approach to monitoring MRD. This collaboration, partially supported by Amgen, will be part of the INSIDE MM-1 study, led by Professor Antonio Palumbo from UofT. Professor Palumbo presented promising results of an earlier study at the 2013 American Society for Clinical Oncology (ASCO) annual meeting. This earlier study, funded by a 2010 Diagnostics Investment Award from the MMRF, set the stage for INSIDE MM-1, a groundbreaking, comparative, clinical disease monitoring trial. More than 400 newly diagnosed MM patients will be enrolled in INSIDE MM-1 and will receive a combination of carfilzomib and lenalidomide, followed by a bone marrow transplant with or without maintenance. Patients will be monitored for MRD using both flow cytometry and Adaptive Biotechnologies’ clonoSEQ MRD test at regular intervals from initial diagnosis for up to five years after initial treatment.
The Multiple Myeloma Research Foundation Appoints Wynton Marsalis to Honorary Board of Directors
Mar 10 15
The Multiple Myeloma Research Foundation (MMRF) announced that Managing and Artistic Director of Jazz at Lincoln Center, Wynton Marsalis has joined the MMRF Honorary Board.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries